Today, Baird Capital portfolio company Prescient, a biopharma product and portfolio strategy firm, announced the acquisition of Strategic North, a global commercial strategy consultancy. The transaction aims to enhance the depth, breadth, and value of services offered to both organizations' pharmaceutical and biotech clients.

Strategic North was founded in 2010 and today employs 70 executives out of its offices in the UK. Strategic North partners with a wide range of global pharmaceutical companies to help them better understand how their customers make decisions with the goal of unlocking the full potential of their brands. The team of research and brand strategy consultants specializes in healthcare internationally. Strategic North aims to drive sustainable brand growth by applying a deep understanding of customer behavior and decision-making with their strategic thinking.

Baird Capital initially invested in Prescient in 2017. The firm sold Prescient to Bridgepoint Development Capital in 2021 and subsequently reinvested to become a minority shareholder.

Baird Capital Partners Europe Limited is authorised and regulated in the United Kingdom by the Financial Conduct Authority.